PCRX Q3 2018 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$83M+23.9% YoY

Gross Profit

$64M77.2% margin

Operating Income

$4M4.9% margin

Net Income

-$640,000-0.8% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-0.8%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$12M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$659M

Total Liabilities

$358M

Stockholders' Equity

$301M

Cash & Equivalents

$231M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$67M	+23.9%
Gross Profit	$64M	$49M	+31.1%
Operating Income	$4M	-$4M	+213.3%
Net Income	-$640,000	-$8M	+91.6%

Revenue Segments

EXPAREL

$82M99%

DepoCyt(e) and Other Products

$482,0001%